Cytolytic nanoparticles attenuate HIV-1 infectivity

Antiviral Therapy

Volumn 18, Issue 1, 2013, Pages 95-103

  Hood, Joshua L ^a   Jallouk, Andrew P ^a   Campbell, Nancy ^a   Ratner, Lee ^a   Wickline, Samuel A ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; MELITTIN; NANOPARTICLE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; INFECTION PREVENTION; NANOEMULSION; NANOPHARMACEUTICS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TOXICITY TESTING; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; VIRUS STRAIN; VIRUS VIRULENCE;

ANTIMICROBIAL CATIONIC PEPTIDES; EPITHELIAL CELLS; FEMALE; HEK293 CELLS; HELA CELLS; HIV INFECTIONS; HIV-1; HUMANS; MELITTEN; NANOPARTICLES; RECEPTORS, CCR5; RECEPTORS, CXCR4; RECEPTORS, HIV; VAGINA;

EID: 84874439828     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2346     Document Type: Article

References (25)

1. Soman NR, Lanza GM, Heuser JM, Schlesinger PH, Wickline SA. Synthesis and characterization of stable luorocarbon nanostructures as drug delivery vehicles for cytolytic peptides. Nano Lett 2008; 8:1131-1136.
2. Soman NR, Baldwin SL, Hu G, et al. Molecularly targeted nanocarriers deliver the cytolytic peptide melittin speciically to tumor cells in mice, reducing tumor growth. J Clin Invest 2009; 119:2830-2842.
3. Shaposhnikova VV, Egorova MV, Kudryavtsev AA, Levitman M, Korystov Yu N. The effect of melittin on proliferation and death of thymocytes. FEBS Lett 1997; 410:285-288.
4. Tu WC, Wu CC, Hsieh HL, Chen CY, Hsu SL. Honeybee venom induces calcium-dependent but caspase-independent apoptotic cell death in human melanoma A2058 cells. Toxicon 2008; 52:318-329.
5. Ownby CL, Powell JR, Jiang MS, Fletcher JE. Melittin and phospholipase A2 from bee (Apis mellifera) venom cause necrosis of murine skeletal muscle in vivo. Toxicon 1997; 35:67-80.
6. Maher S, McClean S. Melittin exhibits necrotic cytotoxicity in gastrointestinal cells which is attenuated by cholesterol. Biochem Pharmacol 2008; 75:1104-1114.
7. Esser AF, Bartholomew RM, Jensen FC, Muller-Eberhard HJ. Disassembly of viral membranes by complement independent of channel formation. Proc Natl Acad Sci U S A 1979; 76:5843-5847.
8. Wachinger M, Kleinschmidt A, Winder D, et al. Antimicrobial peptides melittin and cecropin inhibit replication of human immunodeiciency virus 1 by suppressing viral gene expression. J Gen Virol 1998; 79:731-740.
9. Harmon B, Campbell N, Ratner L. Role of Abl kinase and the Wave2 signaling complex in HIV-1 entry at a posthemifusion step. PLoS Pathog 2010; 6:e1000956.
10. Westervelt P, Trowbridge DB, Epstein LG, et al. Macrophage tropism determinants of human immunodeiciency virus type 1 in vivo. J Virol 1992; 66:2577-2582.
11. Wehrly K, Chesebro B. p24 antigen capture assay for quantiication of human immunodeiciency virus using readily available inexpensive reagents. Methods 1997; 12:288-293.
12. Klein DH, Burtner DB, Trevino LA, Arlauskas RA. Particle size distribution of concentrated perluorocarbon emulsions by sedimentation ield low fractionation. Biomater Artif Cells Immobilization Biotechnol 1992; 20:859-864.
13. Cantin R, Diou J, Belanger D, Tremblay AM, Gilbert C. Discrimination between exosomes and HIV-1: Puriication of both vesicles from cell-free supernatants. J Immunol Methods 2008; 338:21-30.
14. Owada T, Motomura T, Miyashita-Ogawa Y, et al. Antibody masking renders HIV-1 resistant to cationic membrane iltration through alteration of its electrostatic characteristics. J Virol Methods 2001; 94:15-24.
15. das Neves J, Amiji M, Sarmento B. Mucoadhesive nanosystems for vaginal microbicide development: Friend or foe? Wiley Interdiscip Rev Nanomed Nanobiotechnol 2011; 3:389-399.
16. Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP, et al. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS ONE 2010; 5:e9310.
17. Daar ES, Li XL, Moudgil T, Ho DD. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeiciency virus type 1 isolates. Proc Natl Acad Sci U S A 1990; 87:6574-6578.
18. Ashkenazi A, Smith DH, Marsters SA, et al. Resistance of primary isolates of human immunodeiciency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding afinity. Proc Natl Acad Sci U S A 1991; 88:7056-7060.
19. Kennedy PE, Moss B, Berger EA. Primary HIV-1 isolates refractory to neutralization by soluble CD4 are potently inhibited by CD4-Pseudomonas exotoxin. Virology 1993; 192:375-379.
20. Orloff SL, Kennedy MS, Belperron AA, Maddon PJ, McDougal JS. Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeiciency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4. J Virol 1993; 67:1461-1471.
21. Dey B, Del Castillo CS, Berger EA. Neutralization of human immunodeiciency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor. J Virol 2003; 77:2859-2865.
22. Schutten M, Andeweg AC, Bosch ML, Osterhaus AD. Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1. Scand J Immunol 1995; 41:18-22.
23. Sullivan N, Sun Y, Li J, Hofmann W, Sodroski J. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeiciency virus type 1 isolates. J Virol 1995; 69:4413-4422.
24. Agrawal-Gamse C, Lee FH, Haggarty B, et al. Adaptive mutations in a human immunodeiciency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4. J Virol 2009; 83:11005-11015.
25. Hurt CB, Eron JJ, Jr., Cohen MS. Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis 2011; 53:1265-1270.